FY2026 Earnings Forecast for Harrow Issued By William Blair

Harrow, Inc. (NASDAQ:HROW - Free Report) - William Blair decreased their FY2026 EPS estimates for shares of Harrow in a research note issued to investors on Monday, July 14th. William Blair analyst L. Hanbury-Brown now forecasts that the company will earn $1.30 per share for the year, down from their previous estimate of $1.35. William Blair has a "Outperform" rating on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative return on equity of 25.01% and a negative net margin of 10.19%. The business had revenue of $47.83 million for the quarter, compared to analyst estimates of $57.00 million.

Other research analysts have also issued reports about the stock. HC Wainwright raised their target price on shares of Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research note on Monday, May 12th. Cantor Fitzgerald began coverage on shares of Harrow in a research report on Friday. They issued an "overweight" rating and a $76.00 price target on the stock. BTIG Research began coverage on shares of Harrow in a research report on Thursday, June 12th. They issued a "buy" rating and a $62.00 price target on the stock. Finally, B. Riley decreased their price target on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Harrow currently has a consensus rating of "Buy" and an average price target of $63.83.

Harrow Stock Performance

NASDAQ:HROW traded down $1.25 during midday trading on Tuesday, reaching $34.37. The stock had a trading volume of 534,967 shares, compared to its average volume of 498,767. Harrow has a 1-year low of $20.85 and a 1-year high of $59.23. The firm's fifty day simple moving average is $29.45 and its 200-day simple moving average is $28.80. The company has a debt-to-equity ratio of 2.01, a current ratio of 0.91 and a quick ratio of 0.85. The stock has a market capitalization of $1.26 billion, a P/E ratio of -61.37 and a beta of 0.41.

Hedge Funds Weigh In On Harrow

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HROW. GF Fund Management CO. LTD. bought a new position in shares of Harrow in the fourth quarter worth about $25,000. Quarry LP bought a new position in shares of Harrow in the first quarter worth about $32,000. Tower Research Capital LLC TRC raised its stake in shares of Harrow by 769.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after acquiring an additional 1,462 shares during the last quarter. Aquatic Capital Management LLC bought a new position in shares of Harrow in the fourth quarter worth about $78,000. Finally, AlphaQuest LLC raised its stake in shares of Harrow by 452.8% in the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after acquiring an additional 2,889 shares during the last quarter. 72.76% of the stock is currently owned by institutional investors and hedge funds.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.